Promising Approach in Treating Rectal Cancer: Rethinking Radiation Before Surgery Radiation combined with chemotherapy, also known as chemoradiotherapy, is routinely given to people with rectal cancer whose tumours can be removed […]

Predictive Values of Blood-based RNA Signature for the FOLFIRINOX/FOLFOX Response in Advanced Pancreatic Cancer Presently, no widely recognised or established biomarkers are specifically designed to predict the effectiveness of FOLFIRINOX/FOLFOX […]

DIPLOMA Trial: Minimally Invasive Surgery is an Effective Treatment Option for Early-Stage Pancreatic Cancer A notable study, DIPLOMA, led by Abu Hilal, M.D., Ph.D., of the Istituto Ospedaliero Fondazione Poliambulanza in Brescia, Italy, involved a large […]

Personalized mRNA Pancreatic Cancer Vaccine Shows Promising Results in Small Trial Messenger RNA (mRNA) vaccines – famous for preventing symptomatic infection of COVID-19—are starting to show some promise against pancreatic c […]

ESMO Study Confirms Precision Oncology Remains Largely Inaccessible to European Cancer Patients As a European umbrella organisation, DiCE is vocal in addressing the disparities associated with cancer patients’ access to precision medicine […]

Primary and Updated Analyses for DESTINY-Gastric02 Study: Trastuzumab Deruxtecan Continues to Demonstrate Benefit in Metastatic Gastric and Gastro-oesophageal Cancer Human Epidermal Growth receptor 2 (HER2) is a protein involved in normal cell growth, found in small amounts in almost all human cells, including […]

RWE Research in mCRC In a recent article published in the Future Oncology, Patient Advocates and DiCE CEO Zorana Maravic explored and enhanced the understanding of the […]

Manifesto for a Healthier Europe DiCE, together with the EU Health Coalition, urges future EU leaders to prioritise health and life sciences. Ahead of next year’s European […]

EU Commission Approval of Tibsovo® (Ivosidenib) in IDH1-mutated Cholangiocarcinoma The European Commission approved the use of Tibsovo® (Ivosidenib) as monotherapy for the treatment of locally advanced or metastatic […]

Updates in Oesophageal and Gastric Cancer Research, Summer 2023

Liver Cancer Index – Data Gaps  DiCE would like to map liver cancer treatment across the EU. To achieve this, DiCE has started disseminating a survey this spring, primarily among […]

Collaboration with COR2ED – HCC CONNECT

DiCE at the WECAN Retreat 2023 DiCE attended the Workgroup of European Cancer Patient Advocacy Networks (WECAN) retreat on the 20 and 21 April in Frankfurt (Germany). WECAN is […]

Join our Young CRC Patient Focus Group This year, DiCE is working on gaining additional insight into the experiences of young colorectal cancer patients, from symptoms to diagnosis to […]

Shaping Priorities for the EU4Health Funding Programme The Commission conducted in May a targeted consultation on the EU4Health programme’s future priorities, orientation, and needs. DiCE contributed […]

Calling on EU Institutions to Address the Growing Burden of Digestive Cancers Our CEO, Zorana Maravic, joined United European Gastroenterology (UEG) on 26 April at the European Parliament in Brussels to call for more action to […]

Highlights from the EASL Liver Cancer Summit The European Association for the Study of the Liver (EASL) held the Liver Cancer Summit, its annual conference focused on liver cancer in Estoril, […]

Croatian National Policy Event on Digestive Cancers

Productive DISCERN Kick-Off Meeting in Barcelona

SURVEY: Assessing AI Awareness & Perceptions Among Patient Organisations European Patient’s Forum (EPF) is collecting responses to a survey addressed to patients’ organisations or individuals carrying out patient advocacy […]